Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

Dries Deeren, Johan A. Maertens, Tara L. Lin, Yves Beguin, Erik Alcantar-Orozco, Marie-Sophie Dheur, Eytan Breman, Nathalie Braun, Caroline Lonez, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 408.

https://doi.org/10.1182/blood-2021-152413

Published: 2021

Journal Articles

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, MD PhD, Johan A. Maertens, MD PhD, Tara Lin, MD, Yves Beguin, MD PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-139667

Published: 2020

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A. Samer Al-Homsi, MD, Sebastien Anguille, MD, Jason Brayer, PhDMD, Dries Deeren, MD PhD, Nathalie Meuleman, PhD MD, Gareth Morgan, MDPhDFRCP, Taiga Nishihori, MD, Panagiota A. Sotiropoulou, PhD, Laure Twyffels, PhD, Jennifer Bolsee, PhD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139516

Published: 2020

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

NARROW

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Email alerts

ASH Publications

American Society of Hematology

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only